Information  X 
Enter a valid email address

Scancell Holdings PLC Ord 0.1P (SCLP)

Related News

10-May-2019 08:26 AM

Scancell appoints clinical advisory board

Scancell, the developer of novel immunotherapies for the treatment of cancer, has appointed six world-leading clinicians to establish its clinical advisory board. The board will be chaired by professor Robert Coleman and will provide strategic guidance a
15-Feb-2018 08:19 AM

Scancell signs agreement with ISA Pharmaceuticals

Scancell, a developer of novel immunotherapies for the treatment of cancer, has signed a worldwide licensing and collaboration agreement with ISA Pharmaceuticals, a clinical-stage immunotherapy company. ISA's AMPLIVANT adjuvant technology will be us
30-Jan-2018 09:42 AM

Scancell Holdings losses widen

Cancer treatment developer Scancell Holdings said interim losses widened as it invested in research. The company posted a loss of £2.02m, widening from a loss of £1.72m a year earlier. At 9:42am: (LON:SCLP) Scancell Holdings PLC share price
14-Dec-2017 08:07 AM

Scancell forms partnership with Cancer Research

Scancell, a developer of immunotherapies for the treatment of cancer, has partnered with the charity Cancer Research UK to develop Scancell's ImmunoBody vaccine, SCIB2, for the treatment of patients with solid tumours, including non-small cell lung c
13-Sep-2017 07:44 AM

Scancell reports good progress in development of Modi-1

Scancell reported continued good progress in development of Modi-1, the lead product from the Moditope platform in the year to 30 April 2017. HIGHLIGHTS: - Strong survival data for patients with Stage III/IV malignant melanoma on SCIB1 Phase 1/2 clinica
13-Apr-2017 01:07 PM

Scancell changes registered office

Scancell Holdings has changed its registered office address to John Eccles House, Robert Robinson Avenue, Oxford Science Park, Oxford OX4 4GP. At 1:07pm: (LON:SCLP) Scancell Holdings PLC share price was 0p at 13.75p Story provided by StockMarketWir
27-Jan-2016 09:34 AM

Scancell narrows H1 pretax loss

Scancell has narrowed its H1 pretax loss to GBP1.4m, from GBP1.5m. Its cash balance at Oct. 31, 2015, was GBP1.8m, versus GBP3.1m a year ago. Joint-CEO Richard Goodfellow said: "Scancell is in the midst of an exciting transformation. Our focus on
04-Sep-2014 09:55 AM

Higher losses at Scancell Holdings

Scancell Holdings, the developer of novel immunotherapies for the treatment of cancer, has announced a loss of £2,222,954 (2013: loss: £1,901,944) for the year ended 30 April 2014. Group cash balance at 30 April 2014 was £5,566,234 (30 April 2013: £1
09-May-2014 09:06 AM

Scancell director Peter Allen steps down today

Scancell Holdings non-executive director Peter Allen will be stepping down as of today's date. At 9:06am: (LON:SCLP) Scancell Holdings PLC share price was 0p at 32.5p Story provided by
09-Dec-2013 07:39 AM

Scancell Holdings widens H1 pretax loss

Scancell Holdings booked a wider H1 pretax loss of £1.3m, from £0.97m. Most of the loss was linked to development and administration expenses. The results released today from Part 2 of the Phase 1/2 study with the SCIB1 vaccine in advanced melanoma sup
08-Oct-2013 03:25 PM

Scancell schedules AGM

Scancell will hold its annual general meeting at the offices of FTI Consulting, Holborn Gate, 26 Southampton Buildings, London, WC2A 1PB, on 1 November at 11 a.m. At 3:25pm: (LON:SCLP) share price was -0.25p at 29.5p Story provided by StockMarketWi
10-Sep-2013 03:24 PM

Scancell schedules investor day

Scancell Holdings (LON:SCLP), the developer of novel immunotherapies for the treatment of cancer, is to host an Investor Update on Tuesday, 1 October 2013. Joint CEO's, Dr Richard Goodfellow and Professor Lindy Durrant will present an update on Sc
09-Jul-2013 09:09 AM

Development costs lead to an annual loss at Scancell Holdings

Scancell Holdings, the developer of novel immunotherapies for the treatment of cancer, made a loss for the year from continuing operations of £1,901,944 (2012: loss: (£1,930,064)). The loss for the year was £1,901,944 (2012: profit £557,058). There
09-Apr-2013 07:51 AM

Scancell apoints Peter Allen as non-exec director

Scancell Holdings has appointed Peter Allen as a non-executive director, with immediate effect. Story provided by
27-Feb-2013 02:07 PM

Scancell non-exec resigns

Scancell non-executive director Michael Rippon has resigned from the board of the company with immediate effect. Non-executive chairman David Evans said: "I would like to thank Mike for his many years of unstinting service to Scancell from its fou
31-Jan-2013 08:07 AM

Scancell says early SCIB1 trial results encouraging

Scancell Holdings said it had received encouraging preliminary results from Part 1 of the Phase 1/2 clinical trial for its SCIB1 cancer vaccine. This showed "first evidence that the vaccine is producing an immune response in cancer patients, which m
12-Oct-2012 08:33 AM

Scannell moves into profit for the year

Scannell the developer of therapeutic cancer vaccines, reports that as a result of the net income of £2,487,122 from the sale of the antibody portfolio the Group made a profit for the year of £557,058 (2011: loss of £1,649,225). The increase in devel
15-Aug-2012 01:22 PM

Scancell unveils Moditope vaccine technology platform

Therapeutic cancer vaccines specialist Scancell Holdings has unveiled the development of a new platform technology (Moditope) that stimulates the production of killer CD4 T cells with powerful anti-tumour activity. The directors believe that this new
09-Mar-2012 07:47 AM

Scancell wins patent approval

Scancell Holdings has announced that its protein ImmunoBody vaccine patent has been approved in the US. The patent, which has already been approved in Europe and Australia, will further strengthen Scancell's IP position around its proprietary Immun
04-Nov-2011 09:09 AM

Scancell receives £2.85 million payment

Scancell Holdings (LON:SCLP), the developer of therapeutic cancer vaccines, is set to receive a payment of nearly £3 million relating to a historic antibodies sale. The company announced that it had received confirmation from Cephalon, Inc that the condi
25-Oct-2011 07:13 AM

Scancell update on £2.85m payment

Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer vaccines, has provided shareholders with an update on progress towards meeting the trigger for the second tranche payment from the sale of Scancell's antibody portfolio to Arana
30-Jun-2011 11:58 AM

Scancell raises more money for vaccine development

Scancell Holdings, the developer of therapeutic cancer vaccines, made losses of £1.72m. in the year ended 30 April 2011. The losses in the previous year were £1.8m. It has announced a placing of £1.73m. to fund working capital. Scancell has secured lic
31-Jan-2011 11:43 AM

Scancell posts £0.84m H1 operating loss

Vaccines developer Scancell Holdings Plc made an operating loss for the six months to October 31 of £0.84m, against a 2009 restated loss of £0.66m. The company said a reduction in direct costs reflected slower than anticipated recruitment of patients fo
14-Dec-2010 10:36 AM

Scancell Holdings Phase 1 trial slower than expected

Cancer vaccine developer, Scancell Holdings says that the phase 1 clinical trial for SCIBI vaccine for melanoma is progressing at a rate that is slower than expected as a number of patients with advanced melanoma are too ill to enter the study. To accele
07-Sep-2010 12:24 PM

Scancell reports positive vaccine results

Cancer drug developer, Scancell Holdings says that a treatment, based on its ImmunoBody® technology, in conjunction with ImmuneRegen BioSciences, Inc.®'s lead compound, Homspera®, has significantly improved the immune response of the vac
Top categories
Company finder

a d v e r t i s e m e n t